Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

38.43
+0.12000.31%
Post-market: 39.220.7900+2.06%19:11 EST
Volume:5.36M
Turnover:206.00M
Market Cap:22.41B
PE:21.94
High:38.69
Open:38.31
Low:38.28
Close:38.31
52wk High:41.24
52wk Low:24.05
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.99
T/O Rate:1.41%
Dividend:0.87
Dividend Rate:2.26%
EPS(TTM):1.75
EPS(LYR):1.92
ROE:13.11%
ROA:5.22%
PB:3.49
PE(LYR):20.05

Loading ...

Royalty Pharma Q3 Adjusted Ebitda USD 779 Million

THOMSON REUTERS
·
Nov 05

Royalty Pharma : Raised Full Year 2025 Guidance: Portfolio Receipts Expected to Be $3,200 to $3,250 Mln

THOMSON REUTERS
·
Nov 05

Royalty Pharma Buys $310 Million AMVUTTRA Royalty from Blackstone

Reuters
·
Nov 04

Royalty Pharma Keeps Quarterly Dividend at $0.22 a Share, Payable Dec. 10 to Holders of Record on Nov. 14

MT Newswires Live
·
Oct 17

Royalty Pharma plc Announces $0.22 Dividend for Q4 2025

Reuters
·
Oct 17

Citi Sticks to Its Buy Rating for Royalty Pharma (RPRX)

TIPRANKS
·
Oct 13

Royalty Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 11

Royalty Pharma plc to announce third quarter 2025 financial results

Reuters
·
Oct 10

Zenas BioPharma Announces $120 Million Private Placement to Support Global Expansion and Development Programs

Reuters
·
Oct 08

Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating

TIPRANKS
·
Oct 02

Royalty Pharma Initiated at Buy by Goldman Sachs

Dow Jones
·
Sep 30

Royalty Pharma Appoints DR. Ted W. Love as Lead Independent Director

THOMSON REUTERS
·
Sep 29

Press Release: Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Dow Jones
·
Sep 29

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

stock_story_highlight
·
Sep 17

Citi Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
Sep 16

BRIEF-Royalty Pharma Targets Mid-Teens Annual Shareholder Return Over Next 5 Years

Reuters
·
Sep 11

Royalty Pharma plc to Host Investor Day in New York City, Highlighting Strategic Plans and Market Growth

Reuters
·
Sep 11

Royalty Pharma Plc - Targets $4.7 Bln Portfolio Receipts or More by 2030

THOMSON REUTERS
·
Sep 11

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation

THOMSON REUTERS
·
Sep 11

Royalty Pharma Unveils Comprehensive Deloitte Report Highlighting Biopharma Royalty Market Dynamics and Growth Prospects

Reuters
·
Sep 10